Authors: Rahmadhani Tyas Angganawati, Suharjono*, Aghnia Fuadatul Inayah, Ayu Ratnasari,
Master Programme of Clinical Pharmacy, Faculty of Pharmacy,
Airlangga University, 60286, Surabaya, Indonesia
*Corresponding Author. E-mail : shj_ms_id@yahoo.com
Abstract
Systemic Lupus Erythematosus (SLE) is an inflammatory autoimmune disorder which characterized by loss of self-tolerance with autoreactive T and B cell activation leading to production of pathogenic autoantibodies and tissue injury. It can affect several organ systems of the body and the severity varies greatly from mild disorders to diseases with rapid progression and life-threatening. Antimalarial drugs such as chloroquine and hydroxychloroquine are widely used in treating systemic lupus erythematosus (SLE). It has safety profile and broad spectrum of potential beneficial effect, so it can be given in the early diagnosed of SLE. The efficacy of antimalarials, especially hydroxychloroquine (HCQ), in preventing systemic lupus erythematosus (SLE) flares is well demonstrated. In spite of the effect, the adverse effect should be monitored well. The common adverse event is retinopathy, but Hydroxychloroquine is claimed better tolerated than Chloroquine. In this review, we discussed about the known off-label use of antimalarials in systemic lupus erythematosus.
Key Words : Antimalarials, Chloroquine, Hydroxychloroquine, Systemic Lupus Erythematosus
